In addition to classical exercise mimetics, metabolic modulators such as meldonium and trimetazidine may also contribute to the therapeutic potential of the AMPK/SIRT1/PGC-1α axis in MDD [113,114]. The gene discussed is PPARGC1A; the disease is major depressive disorder.